(NASDAQ: LPTX) Leap Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Leap Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast LPTX's revenue for 2029 to be $1,633,960,628, with the lowest LPTX revenue forecast at $1,633,960,628, and the highest LPTX revenue forecast at $1,633,960,628. On average, 1 Wall Street analysts forecast LPTX's revenue for 2030 to be $3,393,068,635, with the lowest LPTX revenue forecast at $3,393,068,635, and the highest LPTX revenue forecast at $3,393,068,635.
In 2031, LPTX is forecast to generate $4,999,679,174 in revenue, with the lowest revenue forecast at $4,999,679,174 and the highest revenue forecast at $4,999,679,174.